Company intelligence / Profile preview

AtheroNova Inc.

Irvine, California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

AtheroNova's lead compound AHRO-001 completed Phase Ib safety trials in Russia with no significant adverse effects reported. The program aimed to demonstrate regression of atherosclerotic plaque using bile-acid based therapy. Further development was halted after the company filed for bankruptcy protection in March 2015[3][6].

Therapeutic areas: Men's HealthCardiovascularNeurology
Modalities: Small molecules (bile acid-based compounds)Natural compounds
Industry: Biotech

Drug pipeline

1 asset

Hyodeoxycholic acid

Partnerships

'OOO CardioNova' (Russian subsidiary of Maxwell Biotech Group)

Beyond the preview

Go deeper on AtheroNova Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtheroNova Inc..

Explore the full profile